Biotechnology

Valion Bio

Valion Bio released FY2026 Q1 earnings on May 14 After-Market EST, actual revenue USD 0, actual EPS USD -2.222

VBIO.US to Release FY2026 Q1 Earnings on May 14 After-Market (BJT)

VBIO.US released FY2025 Q4 earnings on March 30, 2026 (BJT) with actual revenue of USD 0 and EPS of USD 0

VBIO.US released FY2024 Q4 earnings on March 30 (BJT), actual revenue USD 0 (forecast USD 1.43 M), actual EPS USD 0

VBIO.US released FY2024 Annual Earnings on March 30 (BJT), Actual Revenue: USD 0 (Forecast: USD 4.89 M), Actual EPS: USD -19.6784

VBIO.US released FY2025 Annual Earnings on March 30 (BJT), actual revenue USD 0 (forecast USD 8.033 M), actual EPS USD -7.683

Valion Bio released FY2024 9 Months Earnings on November 14, 2025 (EST), with actual revenue of USD 600 K and EPS of USD -26.4502

VBIO.US released FY2024 Q3 earnings on November 14 (BJT), actual revenue USD 126 K (forecast USD 1.26 M), actual EPS USD -3.9293

VALION BIO INC released FY2025 9 Months Earnings on November 14, 2025 (EST), with actual revenue of USD 302K and EPS of USD -6.7111

Valion Bio released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 146K, actual EPS USD -2.0003

Valion Bio released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 156 K, actual EPS USD -4.6429

VBIO.US released FY2024 Semi-Annual earnings on August 14, 2025 (BJT), with actual revenue of USD 474 K and EPS of USD -17.0512

VALION BIO INC released FY2024 Q2 earnings on August 14 (EST), actual revenue USD 140K (forecast USD 1.13M), actual EPS USD -5.3674

VALION BIO INC released FY2025 Q2 earnings on August 14, 2025 (EST), with actual revenue of USD 86K and EPS of USD -2.1922

VBIO.US released FY2024 Q1 earnings on May 15 (BJT), actual revenue USD 334K (forecast USD 1.07M), actual EPS USD -17.1535

VBIO.US released FY2025 Q1 earnings on May 15, 2025 (BJT), actual revenue USD 70K, actual EPS USD -2.5185

< 1B

1B - 5B

5B - 10B

10B - 50B

50B - 100B

100B - 500B

500B - 1T

≥ 1T

Market Value

Total Assets

< 100M

100M - 500M

500M - 1B

≥ 100B

Revenue

0 - 50M

50M - 100M

≥ 10B

Profits

< 0%

0% - 5%

5% - 10%

10 - 15%

15% - 20%

20 - 25%

25% - 30%

>= 30%

ROE(TTM)

= 0%

0% - 1%

1% - 3%

3% - 5%

5% - 8%

8% - 10%

>= 10%

Dividend Yield

0% - 10%

10% - 15%

20% - 30%

30% - 40%

40% - 50%

>= 50%

Net Profit Margin

0 - 0.05

0.05 - 0.1

0.1 - 0.2

0.2 - 0.4

0.4 - 0.6

0.6 - 0.8

0.8 - 1

>= 1

Asset Turnover

< 1.5

1.5 - 2

2 - 3

3 - 5

5 - 10

10 - 15

15 - 20

>= 20

Equity Multiplier

< 10%

10% - 30%

30% - 50%

50% - 70%

70 - 80%

80% - 90%

90% - 95%

>= 95%

Debt Ratio

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

VBIO

Valion Bio (NASDAQ: VBIO) confirmed that the U.S. House Armed Services Committee's FY27 NDAA report directs the Department of Defense to develop a plan for prioritizing radiation/nuclear countermeasures with both prophylactic and therapeutic efficacy. This follows Valion Bio's briefings on its lead candidate, Entolimod, for acute radiation syndrome. The company stated this aligns with national defense needs but clarified the report does not constitute a contract or funding commitment.

StockTitan

Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures | VBIO Stock News

HUMA

PCSA

ICLR

HSCS

In Wednesday's after-market session, several healthcare stocks saw significant movement. Gainers included HeartSciences (+16.5%), Icon (+10.65%), and Processa Pharma (+10.6%). Conversely, losers featured BGM Group (-14.1%), Humacyte (-10.53%), and Valion Bio (-7.97%). The report highlights specific price changes and market capitalizations for these listed companies.

benzinga_article

Humacyte

Processa Pharmaceuticals

ICON

HeartSciences

Aditxt

China SXT Pharmaceuticals

Allarity Therapeutics

Upstream Bio

Azitra

Entrada Therapeutics

HEARTSCIENCES INC C/WTS (TO PUR COM)

Humacyte - CW27

12 Health Care Stocks Moving In Wednesday's After-Market Session

VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME | VBIO Stock News

VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME | VBIO Stock News

Valion Bio (VBIO) reported its Q1 2026 results, marking its first full reporting period post-divestiture of its consumer bioelectronics business. The company advanced its Entolimod platform for medical countermeasures and oncology support, while operating expenses rose to $5.6 million, leading to a net loss of $6.2 million. Valion has $7.2 million in cash and is exploring capital-raising options. Spark's analysis rates VBIO as Neutral due to weak financial performance and mixed technicals. Valion Bio focuses on immunotherapeutics, with its lead candidate, Entolimod, receiving Fast Track and Orphan Drug designations.

Tip Ranks

Valion Bio Reports Q1 Results, Advances Entolimod Platform

Valion Bio (NASDAQ:VBIO) held its Q1 2026 earnings call, discussing its transition from Tivic Health Systems and focus on Entolomid, a TLR5 agonist with FDA designations. The company reported Q1 operating expenses of $5.6 million, driven by its biomanufacturing subsidiary, Velocity Bioworks. Future plans include physician-sponsored studies and GMP manufacturing validation. CEO Michael K. Handley highlighted the company's strategic focus on government engagements and the development of Entolomid and Intelasta, emphasizing a strong foundation for capital allocation and regulatory pathways.

Tivic Health

Valion Bio Q1 2026 Earnings Call: Complete Transcript

Earnings Watch

Valion Bio | 8-K: FY2026 Q1 Revenue: USD 0

Valion Bio's subsidiary, Velocity Bioworks, has secured an exclusive commercial license for LarmorBio's BioScan-NMR™ platform, with the first installation planned for July 2026 in San Antonio. This partnership positions Velocity Bioworks as a strategic player in next-generation NMR diagnostics, enhancing its service offerings and aligning both companies for future growth. Valion Bio is focused on developing immunotherapeutics, including treatments for Acute Radiation Syndrome and oncology supportive care, while Velocity Bioworks serves as a contract development manufacturing organization.

Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform | VBIO Stock News

Ownership	%Owned	Share Chg	Report Date
3i Management LLC	3.41%	No Change	31/03/2026
Avenue Capital Group, LLC	3.24%	No Change	30/09/2025
Geode Capital Management, LLC	2.8%	85.67 K	31/03/2026
Sanctuary Advisors, LLC	1.95%	No Change	31/03/2026
Biostax Corp.	1.95%	No Change	14/05/2025
Marex Group plc	1.89%	18.32 K	31/03/2026
Hudson River Trading LLC	1.35%	No Change	31/03/2026
Jennifer Ernst	1.04%	No Change	26/12/2025
Christina Rizopoulos Valauri	0.61%	No Change	01/04/2026
Michael Kevin Handley	0.35%	2.21 K	18/05/2026

Valion Bio(VBIO.US)

Valuation analysis

Institutional View & Shareholder

Analyst Ratings

Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures | VBIO Stock News

12 Health Care Stocks Moving In Wednesday's After-Market Session

VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME | VBIO Stock News

Valion Bio Reports Q1 Results, Advances Entolimod Platform

Valion Bio Q1 2026 Earnings Call: Complete Transcript